InnoCan Pharma Corporation INNPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 96.40% | -148.72% | 202.47% | -230.00% | -1.37% |
| Total Depreciation and Amortization | -37.50% | -33.33% | 9.09% | 22.22% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -284.98% | 112.10% | -274.66% | 13,293.75% | -101.74% |
| Change in Net Operating Assets | 3,166.67% | -98.91% | 818.30% | -111.93% | 5,478.26% |
| Cash from Operations | 8.50% | 12.91% | -2,740.91% | -96.79% | 86.41% |
| Capital Expenditure | -- | -- | -50.00% | -300.00% | 80.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -200.00% |
| Cash from Investing | -- | -- | -25.00% | -100.00% | 50.00% |
| Total Debt Issued | -55.56% | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | 100.00% | 25.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -82.22% |
| Cash from Financing | -55.56% | -- | 100.00% | -101.96% | -84.64% |
| Foreign Exchange rate Adjustments | 1,200.00% | -233.33% | -- | -100.00% | 1,866.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -280.00% | 89.71% | -3,986.67% | -98.31% | -34.41% |